MIRM Q1 2025 Earnings — Mirum Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MIRMMirum Pharmaceuticals, Inc.

$5B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$112M+61.2% YoY

Gross Profit

$89M79.4% margin

Operating Income

-$15M-13.6% margin

Net Income

-$15M-13.2% margin

EPS (Diluted)

$-0.30

QoQ Revenue Growth

+12.2%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$690M

Total Liabilities

$457M

Stockholders' Equity

$233M

Cash & Equivalents

$212M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$112M	$69M	+61.2%
Gross Profit	$89M	$51M	+72.3%
Operating Income	-$15M	-$26M	+42.6%
Net Income	-$15M	-$25M	+41.9%

Revenue Segments

Product

$112M100%

Geographic Segments

UNITED STATES

$87M78%

Rest Of World

$25M22%